AI-based Clinical Trials Solution Providers Market Outlook:
AI-based Clinical Trials Solution Providers Market size was valued at USD 2.73 billion in 2025 and is expected to reach USD 18.98 billion by 2035, expanding at around 21.4% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of AI-based clinical trials solution providers is evaluated at USD 3.26 billion.
The growth of the market can be attributed to the increasing adoption of AI-based platforms to enhance the accuracy and productivity of clinical trials at different stages. According to the World Health Organization (WHO), the number of newly recruited trials registered on international clinical trial registry platforms (ICTRP) has been steadily increasing.
As the prevalence of various diseases increases, there is a need for new drug discoveries, which goes from a series of trials known as clinical trials, which tests potential treatments in human volunteers to see whether they should be approved for broader use in the general population. A treatment could be a drug, medical device, or biologic, such as a vaccine, blood product, or gene therapy. Potential treatments, however, must be studied in laboratory animals first to determine potential toxicity before they can be tried on people. As technology is advancing, AI-based clinical trials are becoming popular, where artificial intelligence and big data technology are used for extracting medical information. The market is growing owing to the prevalence of fetal diseases like cancer. According to studies, patient recruitment delays account for 85% of drug trial delays and 30% of early trial terminations. Patient eligibility and enrolment are two critical elements for the success of the overall drug study.
